Cide-a and Cide-c belong to the cell death-inducing DNA fragmentation factor-α-like effector family.
Introduction
Cide-a and Cide-c are cell death-inducing DNA fragmentation factor-α-like effector (CIDE) family proteins, and are well known as apoptosis-inducing factors for cultured cells [1, 2] . Recent functional evidence has indicated that Cide-c is localized in lipid droplets of white adipose tissues, and plays a key role in the formation of lipid droplets [3] [4] [5] . Cide-a is also involved in the formation of lipid droplet, like Cide-c [6, 7] , and deficiency of Cide-a has been reported to contribute to enhancement of lipolysis in brown adipose tissues [8] . Furthermore, Cide-a knock-out mice exhibit resistance to obesity [8] . Protein expression of Cide-a and Cide-c has been reported to increase in the liver of obese mice, although it is minimal in normal liver tissues [9] . In addition to their effects on induction of apoptosis, these factors have received considerable attention with regard to their relationship to energy homeostasis and lifestyle-related metabolic disorders through regulation of lipid accumulation [10, 11] .
A number of epidemiological studies as well as clinical studies have demonstrated that intake of fish oil or n-3 polyunsaturated fatty acids (PUFA) contributes to reduction of risk for cardiovascular events (CVE) [12] . EPA is one of the major n-3 PUFAs contained in fish oil, and is known to variety of pharmacological effects, such as serum lipid-lowering activity [13] , anti-platelet activity [14, 15] , anti-inflammatory activity [16, 17] , and inhibitory effects on the progression of arteriosclerosis [18, 19] . In addition to these activities, Japan EPA Lipid Intervention Study (JELIS), a large-scale clinical trial conducted in Japan using highly purified EPA, has revealed that EPA suppressed the onset of CVE [20] .
EPA inhibits the expression of mRNA encoding sterol regulatory element-binding protein-1 (SREBP-1), a transcription factor regulating the biosynthesis of fatty acids and triglyceride, as well as nuclear protein expression [21] , and at least some of the pharmacological activities of EPA are mediated through its inhibitory effects on SREBP-1c [22] . For example, Sekiya and associates have reported that EPA suppressed expression of SREBP-1 in the liver of leptin-deficient ob/ob mouse model of obesity, and ameliorated hepatic steatosis [23] . Moreover, it has been reported that EPA ameliorated signs of nonalcoholic steatohepatitis (NASH) not only in a mouse model [24] but also a clinical trial [25] , suggesting the possibility that EPA might serve as a useful modality for treatment of liver disorders associated with lipid accumulation.
In this study, we demonstrate that Cide-a and Cide-c are closely related to progression of hepatic steatosis with elevation of alanine aminotransferase (ALT), a plasma marker of hepatic injury. We also demonstrate the possibility that expression of Cide-a is regulated by SREBP-1 and EPA.
Materials and Methods
Materials. Highly purified EPA ethyl ester (purity: >98%) was obtained from Nippon Suisan Kaisha. Ethyl palmitate (purity: >95%) was purchased from Wako (Tokyo). Sodium oleate was from Sigma Aldrich (St. Louis, MO) and eicosapentaenoic acid sodium salt was purchased from Nu-Chek-Prep. (Elysian, MN).
Animals and diets. Male C57BL/6J mice (Clea Japan, Tokyo) at 7-9 weeks of age were given free access to water and one of the following three diets. The control group was fed control diet (fish meal-free F1; Funabashi farm, Chiba, Japan Cide-a and Cide-c which were amplified by PCR were cloned into ptk2435 vector to produce mammalian expression plasmids under the control of elongation factor promoter. Human SREBP-1a
and SREBP-1c active form expression plasmids were prepared by subcloning into pCI expression plasmid (Promega, WI) by PCR amplification.
Reporter plasmid construction for promoter analysis of mouse Cide-a and Cide-c. From mouse
Cide-a and Cide-c promoter sequence data and transcription start site (+1) as previously described [26, 27] , we amplified the Cide-a promoter (from -2179 bp to +738 bp) and Cide-c promoter (from -1629 bp to +1269 bp) by PCR and cloned them into pGL4.17 basic plasmid (Promega) for the construction of Cide promoter luciferase plasmid, and performed to ensure fidelity of PCR sequencing amplification.
Statistical analysis. All data were assessed by Student's t-test. The relationships of ALT as an index of liver injury with other liver parameters (triglyceride, total cholesterol, and mRNA expressions of Cide-a, Cide-c, SREBP-1a, SREBP-1c, and PPARγ) were examined by multiple regression analysis using a stepwise method.
Results and Discussion
Following HF/HS diet for 20 weeks, mouse liver exhibited remarkable hepatic steatosis, TG content significantly increased from the control group level of 14 ± 1 mg/g tissue (mean ± S.E.) to Similarly, levels of Cide-a and Cide-c gene expression were approximately 921-fold and 115-fold higher in ob/ob mice than that of C57BL/6J mice, respectively, in excellent agreement with patterns of changes in triglyceride content in the liver and plasma levels of ALT (Fig. 2B ).
In mice, mRNA of Cide-a and Cide-c is highly expressed in brown adipose tissue and white adipose tissue, respectively, whereas Cide-a/Cide-c genes are minimally expressed in normal liver tissue [2, 5, 9] . It has been reported that Cide-a/Cide-c genes are expressed in the liver of aged mice, of type 2 diabetic mice exhibiting steatosis [28] , and of leptin-deficient ob/ob mice [9] . It has also been reported that Cide-a and Cide-c play important roles in the formation of lipid droplets in adipocyte [3] [4] [5] [6] , and that Cide-c might contribute to lipid accumulation in the liver [9] . However, no report has documented a correlation between the onset/progression of hepatic steatosis and Cide-a/Cide-c were originally identified as factors regarding apoptosis, but the relationship between ectopic expression of Cide-a/Cide-c in hepatic steatosis and cell injury remained unclear.
It has been reported that Cide-a mRNA in mouse liver was experimentally induced by treatment with
Wy-14643, a PPARα agonist, though without increase in apoptosis [26] . However, in the present study, there were excellent correlations between plasma level of ALT, a marker of liver injury, and levels of Cide-a/Cide-c gene expression, and the results of multiple regression analysis revealed that mRNA expression of Cide-a/Cide-c significantly contributed to plasma levels of ALT (Table 2) .
Taken together, these findings suggest that it may be possible that Cide-a and Cide-c contribute to hepatic injuries associated with hepatic steatosis, in addition to accumulation of triglyceride.
We also investigated whether ectopic Cide-a and Cide-c expression affects features of the lipid droplets formed by the addition of 200 µM oleic acid. Some large lipid droplets were found in
McA-RH7777 hepatoma cells and Cos-1 cells in which Cide-a and Cide-c gene expression had been induced (Fig. 3A) . This is the first report that Cide-a was indeed involved in formation of lipid droplet in liver-derived cells. Cell numbers and LDH levels in culture media examined in the same experiment indicated that Cide-a and Cide-c gene expression induced cell death at the same time (Fig. 3B ). These in vitro findings supported the in vivo result that Cide-a and Cide-c were involved in the progression of hepatic steatosis and liver injuries associated with hepatic steatosis.
It has been reported that Cide-a and Cide-c gene expression is controlled by PPARα [26] or PPARγ [9] . In the present study, Cide-a and Cide-c gene expression was modulated in parallel with PPARγ gene expression. On the other hand, EPA inhibited mRNA expression of Cide-a, Cide-c, and PPARγ induced by HF/HS (Fig. 1) . Since EPA activates PPARα [29] and PPARγ [30, 31] , these findings are contradictory. Thus, the inhibitory effect of EPA on Cide-a and Cide-c expression was not mediated through activation of PPARα [26] or PPARγ [9] . We therefore investigated direct effects of EPA on Cide-a and Cide-c gene expression in vitro.
EPA inhibited Cide-a promoter activities but not Cide-c promoter activities in the luciferase assay (Fig. 4A) , suggesting that EPA may have different mechanisms of manifestation of inhibitory effects on Cide-a and Cide-c gene expression. SREBP-1 mRNA expression and nuclear protein expression are known to be inhibited by EPA [21] . In the present study, SREBP-1c and Cide-a and 8
Cide-c in the liver were modulated in similar fashion (Fig. 1) . We then examined the effects of SREBP-1 on Cide-a and Cide-c promoter activities. When SREBP-1a or SREBP-1c was co-transfected, Cide-a promoter activities were markedly increased, whereas Cide-c promoter activity was only slightly affected by SREBP-1s (Fig. 4B) . These results are in agreement with the effects of EPA on Cide-a and Cide-c promoter activities, strongly suggesting that the inhibitory effect of EPA on Cide-a promoter activity is mediated through SREBP-1.
In summary 
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Delipidated serum was prepared from immobilized fetal bovine serum according to a reference [32] .
Luciferase activity was measured at 1 day after transfection using the Dual Glo Luciferase assay kit 
